Elevance Health (ELV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
With a strengthening commercial business, ELV is seeing steady membership growth.
Elevance Health remains a buy with its strong fundamentals. An added bonus is its defensive nature during the tariff wars. Regulatory changes under Trump's administration and AI integration are key factors influencing ELV's future growth and efficiency improvements.
Elevance Health (ELV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Due to heightened political uncertainty, health insurer and pharmacy benefit manager, Elevance Health, continues to be shunned by the market. While I focused on the challenges and risks in my last article, in this update, I give three reasons why I feel comfortable taking a contrarian position with ELV stock. Given that Elevance is in financially very healthy shape and is strongly profitable, there is obviously a large margin of safety from an operational perspective.
Dividend growth investing can offer high-quality stocks, with small dividends growing in the 10-15% range, providing impressive investment opportunities. Diversified, large-cap companies with strong revenue, earnings, and dividend growth, are reliable characteristics of such dividend growth companies investors can count on. The companies I'll highlight have strong insider holdings, reliable growing dividends, and current or potential for share buybacks, offering stability and potentially strong capital gains.
Elevance Health says its acquisition of Verily's Granular Insurance Company is designed to bolster its offerings to self-funded employer clients. Financial terms of the deal aren't being disclosed, an Elevance spokeswoman said.
With the stock market going through its first earnings season of 2025, companies are making important announcements. This includes the approval of share buyback programs, as well as dividend increases.
The healthcare industry is undergoing rapid transformation, driven by advancements in technology, artificial intelligence, and data analytics. Companies at the forefront of this shift are redefining how healthcare providers manage data, deliver care, and enhance patient outcomes.
ELV's fourth-quarter results benefit from rising premiums. However, higher expenses and attrition in Medicaid membership partially offset the positives.